tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk Effects of Tirzepatide in Type

Phentermine is not recommended for use in pediatric patients 16 years of age

Shed guarantees that new GLP-1 users will lose at least 10 percent of their starting body weight within nine months or receive a full refund

These are preliminary research findings and not peer reviewed

The monthly rate covers medication at any dose, unlimited provider visits, one-on-one behavior coaching, nutritional counseling with a dietitian, guided fitness sessions, a macro and weight tracker, virtual community courses, and one-day shipping

Discrepancies identified during the screening, full-text, and data extraction process were resolved through consensus

[2] [3] NICE guidance for obesity management acknowledges this uncertainty whilst supporting the use of these agents when clinically appropriate, emphasising the importance of patient selection and monitoring